pharma · Melanoma · HIV Infections
Bristol Myers Squibb
Bristol-Myers Squibb
NovaPharmaNews editorial coverage mentioning Bristol Myers Squibb — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 3401 Princeton Pike, Lawrence Township, NJ 08648, US
- Employees
- 38,146
- Programs
- 40
- Drugs
- 17
- Patents
- 25
News & analysis
NovaPharmaNews articles mentioning Bristol Myers Squibb — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Bristol Myers Squibb — regulatory, clinical, and market analysis.
Cobenfy meets endpoint in Bristol Myers Squibb’s Alzheimer’s psychosis trial
Bristol Myers Squibb’s Cobenfy has reached a key milestone in Alzheimer’s psychosis, expanding the story beyond its approved schizophrenia use. Analysts should watch ADEPT-2 execution, enrollment changes, and whether the signal supports a broader development path.
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.
This Week’s Biopharma News: New Approvals, Appeals, and AI
This week's biopharma news highlights significant FDA approvals for Datroway and Hepcludex, a key appeal win for Outlook regarding bevacizumab, and promising Phase 3 data for BioMarin's VOXZOGO. The evolving landscape also sees increased integration of AI in drug development and regulatory processes.
BMS-Hengrui $15B Deal: Strategic Implications for Pharma Executives
Bristol Myers Squibb's significant $15 billion partnership with Hengrui Pharma signals a strategic shift, leveraging China's R&D capabilities for early-stage assets. This deal offers valuable insights for pharmaceutical business development and investment teams.
#ASCO26: Insights on VEGF Bispecifics from BioNTech-BMS and Pfizer-3SBio
This article delves into the new data released at ASCO26 regarding VEGF bispecifics from BioNTech-BMS and Pfizer-3SBio, highlighting implications for the pharmaceutical industry.
BMS Expands in Texas While Novartis Faces Tenant Challenges
Bristol Myers Squibb is planning a new campus in Texas, while Novartis is facing eviction issues with a tenant in Slovenia. These developments could reshape the competitive landscape.
Analysis of BMS-Hengrui's $15B Deal and Its Implications
This article analyzes the recent $15B deal between BMS and Hengrui, the impact of Takeda's layoffs, and Daiichi's strategic focus on oncology.